PDF(Sci-hub)
Abstract：
Schizophrenia is a chronic and severe mental disorder characterized by positive, negative, and cognitive symptoms. Negative symptoms are usually present from the prodromal phase; early diagnosis and management of negative symptoms is a major health concern since an insidious onset dominated by negative symptoms is associated with a worse outcome. Antipsychotic medications, which are effective for treating positive symptoms, are generally ineffective for treating negative or cognitive symptoms. We present a 23-year-old woman showing severe symptoms at her first visit to our department. The patient\'s parents reported that their daughter had experienced several years of psychosocial decline and putative psychiatric symptoms, but no medical attention had been previously sought; as such, the diagnosis of schizophrenia with predominantly negative symptoms was very much delayed. Early onset of schizophrenia, longer duration of untreated psychosis, and severe negative symptoms, which have limited treatment options, suggested a poor prognosis. We initiated monotherapy with cariprazine, a novel antipsychotic that has recently been proven efficacious in treating schizophrenia with predominantly negative symptoms. This report describes a 52-week cariprazine treatment regimen and follows the patient\'s impressive clinical improvement confirmed by PANSS and CGI scores, and psychological tests.
摘要：
精神分裂症是一种慢性和严重的精神障碍，其特征是阳性，负,和认知症状。阴性症状通常出现在前驱阶段；阴性症状的早期诊断和管理是主要的健康问题，因为以阴性症状为主的阴险发作与较差的结果有关。抗精神病药物,对治疗阳性症状有效，通常对治疗阴性或认知症状无效。我们介绍了一名23岁的妇女，她在第一次访问我们部门时表现出严重的症状。患者的父母报告说，他们的女儿经历了几年的社会心理衰退和推定的精神症状，但是以前没有寻求医疗护理；因此，以阴性症状为主的精神分裂症的诊断延迟很多.早发性精神分裂症,未治疗的精神病持续时间较长，和严重的阴性症状，治疗选择有限，提示预后不良。我们开始用卡利拉嗪单药治疗,一种新的抗精神病药，最近被证明对主要为阴性症状的精神分裂症有效。本报告描述了52周卡利拉嗪治疗方案，并遵循PANSS和CGI评分证实的患者令人印象深刻的临床改善，和心理测试。
